LABIXIAOXIN (01262) announced its interim results for the six months ended June 30, 2025. The company reported revenue of RMB 516 million, representing a 4.5% year-on-year increase. Profit attributable to shareholders reached RMB 2.524 million, compared to a loss of RMB 43.645 million in the same period last year, achieving a turnaround from loss to profit. Basic earnings per share stood at RMB 0.01.